News

Marc Boutin Appointed as New CEO of Center for Innovation

Marc Boutin Appointed as New CEO of Center for Innovation

Marc Boutin Takes the Helm as New President & CEO

The Center for Innovation & Value Research has announced the exciting appointment of Marc Boutin as their new President and Chief Executive Officer. Bringing a rich background as a family caregiver, patient advocate, and executive, Boutin's lived experiences will greatly inform his leadership strategies at the Center. His track record spans over twenty years where he has dedicated his efforts to advancing patient-centered health policy and forging partnerships across various sectors.

Significant Experience in Patient Advocacy

Before joining the Center, Boutin served as the Global Head of Patient Engagement at Novartis. In this role, he was instrumental in creating a robust patient engagement and advocacy framework that was integrated into research and development and overall enterprise decision making. His leadership in this capacity led to clearer trial endpoints and enhanced development processes, helping to reduce complexities while building stronger narratives that resonated with payers, regulators, and patient organizations.

A Legacy of Leadership at the National Health Council

Boutin’s extensive experience also includes nearly two decades at the National Health Council (NHC). Known for elevating the patient voice, Boutin spent five years as President and CEO, a tenure marked by significant growth in core revenue and membership expansion. His ability to strengthen governance and unite various stakeholders around health policy not only benefitted the organization but also fostered a more robust healthcare dialogue.

Recognition of Exceptional Leadership Skills

Throughout his career, Boutin has been acclaimed for his capacity to bridge diverse interests. His efforts to bring together patients, researchers, policymakers, and industry leaders have been foundational in translating complex healthcare issues into tangible action plans that prioritize outcomes important to patients. Stacy Lloyd, Chair of the Center's Board of Directors, emphasized, "Marc brings an extraordinary combination of mission-driven leadership, policy credibility, and operational discipline. His proven ability to foster consensus among diverse stakeholders is invaluable as the healthcare sector seeks to define and measure value consistently."

Vision for the Future of the Center

In his new role, Boutin is committed to partnering closely with the Board and staff to realize the Center's strategic vision. This includes broadening and diversifying financial resources, forging stronger partnerships, and ensuring that the voices of patients remain at the forefront of all research initiatives and policy engagements. His outlook reflects a commitment to healthcare that is both evidence-based and equitable.

A Commitment to Patient-Centered Outcomes

Expressing his enthusiasm for his new position, Boutin stated, "I am honored to join the Center at such an important moment. The Center has built a strong reputation as a credible, patient-centered voice in value research and policy. I am excited to work with the Board, staff, members, and partners to expand the Center's impact, ensuring that healthcare decisions are informed by rigorous evidence and the outcomes that matter to patients."

Conclusion and Transition

Marc Boutin succeeds Jason Spangler and will relocate to the Mid-Atlantic region to undertake this vital role. His appointment marks a new chapter for the Center for Innovation & Value Research as it strives to enhance its influence in the healthcare landscape and deliver on its promise of patient-centered value delivery.

Frequently Asked Questions

What is the main focus of the Center for Innovation & Value Research?

The Center focuses on advancing healthcare approaches that prioritize outcomes significant to patients.

Who is Marc Boutin?

Marc Boutin is the newly appointed President and CEO of the Center, with extensive experience in patient advocacy.

Previously, what position did Marc hold before joining the Center?

Boutin was the Global Head of Patient Engagement at Novartis.

How has Boutin contributed to advocacy in healthcare?

He has a strong history of uniting diverse stakeholders around shared healthcare goals and advancing patient-focused policies.

What vision does Boutin have for his new role?

He aims to enhance the Center's strategic vision and ensure patient perspectives remain at the forefront of all initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 209

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 137

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Millrose Faces Securities Fraud Suit Amidst Decline

Updated Category News Views 171

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 251

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 98

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 136

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 216

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonnet BioTherapeutics to Showcase Innovations in Immunotherapy

Updated Category News Views 116

Sonnet BioTherapeutics Advances in Immunotherapy Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) is making significant strides in the field of oncology, thanks to its innovative approach to immunotherapeutic drug development. The company recently announced an exciting opportunity to present its research at an esteemed conference dedicated to cancer research. Exciting...

Continue Reading
Win $1,500 for a Transformative First-Class Flight Experience

Updated Category News Views 129

Transform Your Travel with Upgraded Points' Contest Upgraded Points presents an exciting opportunity for travelers to experience the luxury of first-class flying without the usual financial burden. With the newly launched contest, one lucky winner will be awarded $1,500 to upgrade their domestic round-trip flight to first class and share their journey. This contest is...

Continue Reading
Florida Cancer Specialists Expands Team with Dinesh Keerty, MD

Updated Category News Views 135

Florida Cancer Specialists Welcomes Dr. Dinesh Keerty Florida Cancer Specialists & Research Institute, known for its commitment to outstanding cancer care, is excited to introduce Dr. Dinesh Keerty, a seasoned medical oncologist and hematologist, to its expanding team. He will be serving patients at two prominent locations: one on Medical Center Drive and another on...

Continue Reading
Glen Burnie Bancorp Reports Q3 2024 Results with Insights

Updated Category News Views 87

Glen Burnie Bancorp Financial Performance Overview Glen Burnie Bancorp (NASDAQ: GLBZ) has recently shared its financial results for the third quarter of 2024, revealing a net income of $129,000, equating to $0.04 per share, which reflects a significant decline from the previous year's $551,000 or $0.19 per share. The income for the nine-month period ending September 30,...

Continue Reading
Fifth Third’s Newline™ Recognized as Top Embedded Finance Solution

Updated Category News Views 287

Newline™ by Fifth Third Receives Prestigious Award Newline™ by Fifth Third has recently been celebrated as the Best New Embedded Finance Platform at the Big Bank Theory Awards, organized by Tearsheet. This award showcases the innovation and leadership present in the financial technology sector, particularly highlighting how companies are transforming the banking...

Continue Reading